dc.contributor.author | Ma, Qianqian | |
dc.date.accessioned | 2017-06-07T11:08:13Z | |
dc.date.available | 2017-06-07T11:08:13Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1178-6930 | |
dc.identifier.uri | http://hdl.handle.net/10900/76559 | |
dc.language.iso | en | en |
dc.publisher | Dove Medical Press Ltd | de_DE |
dc.relation.uri | http://dx.doi.org/10.2147/OTT.S100499 | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject.ddc | 570 | de_DE |
dc.subject.ddc | 610 | de_DE |
dc.title | Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer | de_DE |
dc.type | Article | de_DE |
utue.quellen.id | 20160915142648_02255 | |
utue.publikation.seiten | 959-976 | de_DE |
utue.personen.roh | Ma, Bo | |
utue.personen.roh | Ma, Qianqian | |
utue.personen.roh | Wang, Hongqiang | |
utue.personen.roh | Zhang, Guolei | |
utue.personen.roh | Zhang, Huiying | |
utue.personen.roh | Wang, Xiaohong | |
dcterms.isPartOf.ZSTitelID | Oncotargets and Therapy | de_DE |
dcterms.isPartOf.ZS-Volume | 9 | de_DE |
utue.fakultaet | 04 Medizinische Fakultät |
Dateien | Größe | Format | Anzeige |
---|---|---|---|
Zu diesem Dokument gibt es keine Dateien. |